Exicure Q2 FY26 net loss narrows 57% to $1.12 million; reports no revenue

GPCR USA milestone becomes payable

GPCR USA’s Phase 2 trial completed in January 2026; a $1 million milestone became payable in Q2 2026, expected to be settled in shares.

Expense reductions drive the quarterly improvement

Research and development expense dropped 81% to $174,000; general and administrative costs declined 41% to $889,000.

Cash balance declines and going-concern risk remains

Cash and cash equivalents fell to $1.7 million at June 30, 2026 from $3.7 million at Dec. 31, 2025; substantial doubt was flagged on going concern.

Quarterly results narrow loss but revenue remains nil

Exicure posted a net loss of $1.12 million, narrowing 57% from the prior-year quarter, while revenue was flat at no revenue.

GPCR USA milestone becomes payable

Expense reductions drive the quarterly improvement

Cash balance declines and going-concern risk remains

Quarterly results narrow loss but revenue remains nil

Related News

Glass House Brands Q2 2026 gross margin slides as production costs rise, company says

Voyager Technologies recasts prior financials after combining defense and space segments

Strategy adopts Digital Credit Capital Framework, sets USD Reserve floor for preferred dividends and debt interest

Sources

Exicure Q2 FY26 net loss narrows 57% to $1.12 million; reports no revenue

GlucoTrack FY26 Q2 net loss narrows 19.8% to USD 3.81 million

Envue Medical - Stockholders Approve Reverse Stock Split At Ratio Between 1-For-2 And 1-For-50